4//SEC Filing
Holland David 4
Accession 0001104659-24-101113
CIK 0001267602other
Filed
Sep 17, 8:00 PM ET
Accepted
Sep 18, 9:53 PM ET
Size
27.8 KB
Accession
0001104659-24-101113
Insider Transaction Report
Form 4
Holland David
Sr. VP of Sales & Marketing
Transactions
- Disposition to Issuer
Common Stock
2024-09-16−187,756→ 0 total - Disposition to Issuer
Employee Stock Option (Right to Buy)
2024-09-16−14,000→ 0 totalExercise: $6.75Exp: 2030-01-09→ Common Stock (14,000 underlying) - Disposition to Issuer
Employee Stock Option (Right to Buy)
2024-09-16−100,000→ 0 totalExercise: $3.38Exp: 2033-11-21→ Common Stock (100,000 underlying) - Disposition to Issuer
Employee Stock Option (Right to Buy)
2024-09-16−26,250→ 0 totalExercise: $4.96Exp: 2032-01-03→ Common Stock (26,250 underlying) - Disposition to Issuer
Employee Stock Option (Right to Buy)
2024-09-16−290,000→ 0 totalExercise: $1.16Exp: 2028-01-21→ Common Stock (290,000 underlying) - Disposition to Issuer
Employee Stock Option (Right to Buy)
2024-09-16−16,875→ 0 totalExercise: $5.01Exp: 2031-01-06→ Common Stock (16,875 underlying) - Disposition to Issuer
Employee Stock Option (Right to Buy)
2024-09-16−150,000→ 0 totalExercise: $1.18Exp: 2027-01-19→ Common Stock (150,000 underlying) - Disposition to Issuer
Employee Stock Option (Right to Buy)
2024-09-16−125,000→ 0 totalExercise: $2.47Exp: 2026-01-03→ Common Stock (125,000 underlying) - Disposition to Issuer
Employee Stock Option (Right to Buy)
2024-09-16−170,000→ 0 totalExercise: $0.86Exp: 2029-01-22→ Common Stock (170,000 underlying) - Disposition to Issuer
Employee Stock Option (Right to Buy)
2024-09-16−27,971→ 0 totalExercise: $1.33Exp: 2016-10-12→ Common Stock (27,971 underlying) - Disposition to Issuer
Employee Stock Option (Right to Buy)
2024-09-16−125,000→ 0 totalExercise: $5.51Exp: 2025-01-08→ Common Stock (125,000 underlying)
Footnotes (2)
- [F1]Pursuant to the Agreement and Plan of Merger, dated as of June 21, 2024 (the "Merger Agreement"), by and among the Issuer, ANI Pharmaceuticals, Inc., a Delaware corporation ("Parent") and ANIP Merger Sub INC., a Delaware corporation and a wholly owned indirect subsidiary of Parent, as of the effective time of the merger (the "Effective Time"), each share of common stock was converted into the right to receive (i) $5.50 in cash, without interest (such amount, the "Closing Cash Consideration") and (ii) one contingent value right ("CVR") representing the right to receive contingent cash payments subject to the achievement of certain milestones and the terms and conditions set forth in a contingent value rights agreement entered into between Parent and a rights agent (the consideration contemplated by (i) and (ii), together, the "Merger Consideration").
- [F2]Pursuant to the terms of the Merger Agreement, at the Effective Time, each stock option granted by the Issuer to purchase shares (each, an "Option") that was outstanding and unvested immediately prior to the Effective Time vested in full, and each Option that was outstanding and unexercised which had a per share exercise price that was less than the Closing Cash Consideration was converted into the right to receive the sum of an amount in cash (without interest and subject to deduction for any required withholding as contemplated in the Merger Agreement) equal to: (A) the excess, if any, of the Closing Cash Consideration over the exercise price per share of such Option; multiplied by the number of shares underlying such Option and (B) one CVR.
Documents
Issuer
ALIMERA SCIENCES INC
CIK 0001267602
Entity typeother
Related Parties
1- filerCIK 0001489532
Filing Metadata
- Form type
- 4
- Filed
- Sep 17, 8:00 PM ET
- Accepted
- Sep 18, 9:53 PM ET
- Size
- 27.8 KB